Skip to main content
SpringerLink
Log in

Präventionsstrategien beim Ovarialkarzinom

Aktuelle Möglichkeiten und Perspektiven

Prevention strategies for ovarian cancer

Current possibilities and perspectives

  • Leitthema
  • Published:
Der Gynäkologe Aims and scope

Zusammenfassung

Das Ovarialkarzinom wird zumeist in fortgeschrittenem Stadium mit entsprechend schlechter Prognose diagnostiziert. Prävention und Screening könnten diesen fatalen Verlauf beeinflussen. Charakterisierung und Identifikation der Risikogruppen, bereits verfügbare präventive Maßnahmen fördern und mögliche in Studien evaluieren, Verbesserung der Diagnostik und Evaluation möglicher Screeningmethoden – dies sind einige Aspekte des Problemfeldes. Betrachtet werden hormonelle Kontrazeption, weitere endokrine und chemopräventive Optionen sowie chirurgische Aspekte. Die Bedeutung von nichthereditären Risiken, welche die Inzidenz des Ovarialkarzinoms erhöhen, wird erörtert. Bereits heute bestehen Interventions- und Vermeidungsmöglichkeiten zur Prävention des Ovarialkarzinoms, die mit diagnostischen Maßnahmen verbunden werden können. Sekundär- und Tertiärprävention werden diskutiert.

Abstract

Ovarian cancer is most often diagnosed at an advanced disease stage with reduced or poor prognosis. This fatal course of disease might be influenced by preventive and screening measures. Characterization and identification of populations especially at risk, promotion of already known preventive strategies, improvement of diagnostic tools, and evaluation of new compounds and potential screening instruments are some aspects for discussion. Hormonal contraception, other endocrine therapies and chemopreventive agents, and surgical interventions are critically reviewed. Factors increasing the nonhereditary risk for ovarian cancer are considered. Today, intervention and avoidance strategies are available to influence the ovarian cancer risk; these should be combined with appropriate diagnostic procedures. Secondary and tertiary prevention in ovarian cancer is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Declaration of Helsinki. http://www.wma.net/e/ethicsunit/helsinki.htm

  2. Ries LAG, Hartge P, Trimble E (1993) Ovary. In: Miller BA, Ries LAG, Hankey BF et al. (eds) SEER Cancer Statistics Review 1973–1990. National Cancer Institute NIH Pub 93 2789

  3. Edwards BK, Brown ML, Wingo PA et al. (2005) Annual report to the nation on the status of cancer 1975-2002 featuring population-based trends in cancer treatment. J Natl Cancer Inst 97(19): 1407–1427

    PubMed  Google Scholar 

  4. Gondos A, Holleczek B, Arndt V et al. (2007) Trends in population-based cancer survival in Germany: to what extent does progress reach older patients? Ann Oncol 18 (7): 1253–1259

    PubMed  CAS  Google Scholar 

  5. Schmalfeldt B, du Bois A, Burges A et al. (2006) Diagnosis and treatment of malignant ovarian tumors 2005: recommendations of the Kommission Ovar of the AGO. Zentralbl Gynakol 128(1): 11–17

    PubMed  CAS  Google Scholar 

  6. American Cancer Society (2003) Cancer Facts and Figures 2003. http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf

  7. Hogg R, Friedlander M (2004) Biology of epithelial ovarian cancer: implications for screening women at high genetic risk. J Clin Oncol 22(7): 1315–1327

    PubMed  Google Scholar 

  8. Wimberger P, Lehmann N, Kimmig R et al. (2007) Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 106(1): 69–74

    PubMed  Google Scholar 

  9. Du Bois A, Rochon J, Lamparter C, Pfisterer J (2005) Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer 15(2): 183–191

    Google Scholar 

  10. Adami HO, Hsieh CC, Lambe M et al. (1994) Parity, age at first childbirth, and risk of ovarian cancer. Lancet 344(8932): 1250–1254

    PubMed  CAS  Google Scholar 

  11. Lux MP, Fasching PA, Beckmann MW (2006) Hereditary breast and ovarian cancer: review and future perspectives. J Mol Med 84(1): 16–28

    PubMed  Google Scholar 

  12. Berliner JL, Fay AM (2007) Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns 16(3): 241–260

    PubMed  Google Scholar 

  13. Trimble EL, Karlan BY, Lagasse LD, Hoskins WJ (1991) Diagnosing the correct ovarian cancer syndrome. Obstet Gynecol 78(6): 1023–1026

    PubMed  CAS  Google Scholar 

  14. (1993) Genetic risk and screening techniques for epithelial ovarian cancer. ACOG Committee Opinion: Committee on Gynecologic Practice. Number 117–December 1992. Int J Gynaecol Obstet 41(3): 321–323

  15. Risch HA, McLaughlin JR, Cole DE et al. (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68 (3): 700–710

    PubMed  CAS  Google Scholar 

  16. Lancaster JM, Wooster R, Mangion J et al. (1996) BRCA2 mutations in primary breast and ovarian cancers. Nat Genet 13(2): 238–240

    PubMed  CAS  Google Scholar 

  17. Thompson D, Easton DF (2002) Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18): 1358–1365

    PubMed  CAS  Google Scholar 

  18. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351(24): 2519–2529

    PubMed  CAS  Google Scholar 

  19. Brose MS, Rebbeck TR, Calzone KA et al. (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94(18): 1365–1372

    PubMed  CAS  Google Scholar 

  20. Struewing JP, Hartge P, Wacholder S et al. (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336(20): 1401–1408

    PubMed  CAS  Google Scholar 

  21. Rubin SC, Benjamin I, Behbakht K et al. (1996) Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 335(19): 1413–1416

    PubMed  CAS  Google Scholar 

  22. Majdak EJ, Debniak J, Milczek T et al. (2005) Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. Cancer 104(5): 1004–1012

    PubMed  Google Scholar 

  23. Collaborative Group on Epidemiological Studies of Ovarian C, Beral V, Doll R, Hermon C et al. (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371(9609): 303–314

    Google Scholar 

  24. Trimble EL, Davis J, Disaia P et al. (2007) Clinical trials in gynecological cancer. Int J Gynecol Cancer 17(3): 547–556

    PubMed  CAS  Google Scholar 

  25. National Institutes of Health (NIH). http://www.clinicaltrials.gov/. (Zugriff: 31.07.2006)

  26. Pauling L, Moertel C (1986) A proposition: megadoses of vitamin C are valuable in the treatment of cancer. Nutr Rev 44(1): 28–32

    Article  PubMed  CAS  Google Scholar 

  27. Huang HY, Caballero B, Chang S et al. (2006) Multivitamin/mineral supplements and prevention of chronic disease. Evid Rep Technol Assess (Full Rep) (139): 1–117

    Google Scholar 

  28. Cho E, Hunter DJ, Spiegelman D et al. (2006) Intakes of vitamins A, C and E and folate and multivitamins and lung cancer: a pooled analysis of 8 prospective studies. Int J Cancer 118(4): 970–978

    PubMed  CAS  Google Scholar 

  29. Poulter JM, White WF, Dickerson JW (1984) Ascorbic acid supplementation and five year survival rates in women with early breast cancer. Acta Vitaminol Enzymol 6(3): 175–182

    PubMed  CAS  Google Scholar 

  30. Kastelein JJ, Akdim F, Stroes ES et al. (2008) Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358 (14): 1431–1443

    PubMed  CAS  Google Scholar 

  31. Hankinson SE, Hunter DJ, Colditz GA et al. (1993) Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study. JAMA 270 (23): 2813–2818

    PubMed  CAS  Google Scholar 

  32. Modugno F, Ness RB, Allen GO et al. (2004) Oral contraceptive use reproductive history and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol 191(3): 733–740

    PubMed  Google Scholar 

  33. La Vecchia C, Tavani A, Franceschi S, Parazzini F (1996) Oral contraceptives and cancer. A review of the evidence. Drug Saf 14(4): 260–272

    Google Scholar 

  34. (2008) The case for preventing ovarian cancer. Lancet 371(9609): 275

  35. Narod SA, Risch H, Moslehi R et al. (1998) Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group. N Engl J Med 339(7): 424–428

    PubMed  CAS  Google Scholar 

  36. McLaughlin JR, Risch HA, Lubinski J et al. (2007) Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 8(1): 26–34

    PubMed  CAS  Google Scholar 

  37. Modan B, Hartge P, Hirsh-Yechezkel G et al. (2001) Parity oral contraceptives and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345(4): 235–240

    PubMed  CAS  Google Scholar 

  38. Zheng H, Kavanagh JJ, Hu W et al. (2007) Hormonal therapy in ovarian cancer. Int J Gynecol Cancer 17(2): 325–338

    PubMed  CAS  Google Scholar 

  39. Makar AP (2000) Hormone therapy in epithelial ovarian cancer. Endocr Relat Cancer 7(2): 85–93

    PubMed  CAS  Google Scholar 

  40. Syed V, Ho SM (2003) Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL. Oncogene 22(44): 6883–6890

    PubMed  CAS  Google Scholar 

  41. Kangas L, Gronroos M (1990) Antitumor effects of combination toremifene and medroxyprogesterone acetate (MPA) in vitro and in vivo. J Steroid Biochem 36(3): 253–257

    PubMed  CAS  Google Scholar 

  42. Yancik R (1993) Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71(2): 517–523

    PubMed  CAS  Google Scholar 

  43. Rosenberg L, Palmer JR, Zauber AG et al. (1994) A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139(7): 654–661

    PubMed  CAS  Google Scholar 

  44. Schildkraut JM, Calingaert B, Marchbanks PA et al. (2002) Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 94(1): 32–38

    PubMed  CAS  Google Scholar 

  45. Anderson GL, Judd HL, Kaunitz AM et al. (2003) Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA 290(13): 1739–1748

    PubMed  CAS  Google Scholar 

  46. Riman T, Dickman PW, Nilsson S et al. (2002) Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 156(4): 363–373

    PubMed  Google Scholar 

  47. Rossouw JE, Anderson GL, Prentice RL et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288(3): 321–333

    PubMed  CAS  Google Scholar 

  48. Brinton LA, Gridley G, Persson I et al. (1997) Cancer risk after a hospital discharge diagnosis of endometriosis. Am J Obstet Gynecol 176(3): 572–579

    PubMed  CAS  Google Scholar 

  49. Ness RB, Cottreau C (1999) Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 91(17): 1459–1467

    PubMed  CAS  Google Scholar 

  50. Risch HA, Howe GR (1995) Pelvic inflammatory disease and the risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 4(5): 447–451

    PubMed  CAS  Google Scholar 

  51. Landen CN jr, Birrer MJ, Sood AK (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26(6): 995–1005

    PubMed  Google Scholar 

  52. Sharma R, Hook J, Kumar M, Gabra H (2008) Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur J Cancer 44(2): 251–256

    PubMed  Google Scholar 

  53. Meier CR, Schmitz S, Jick H (2002) Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 22(3): 303–309

    PubMed  CAS  Google Scholar 

  54. Schildkraut JM, Moorman PG, Halabi S et al. (2006) Analgesic drug use and risk of ovarian cancer. Epidemiology 17(1): 104–107

    PubMed  Google Scholar 

  55. Barnes MN, Chhieng DF, Dreher M et al. (2005) Feasibility of performing chemoprevention trials in women at elevated risk of ovarian carcinoma: Initial examination of celecoxib as a chemopreventive agent. Gynecol Oncol 98(3): 376–382

    PubMed  CAS  Google Scholar 

  56. Harris RE (2007) Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem 42: 93–126

    Article  PubMed  Google Scholar 

  57. Harris RE, Beebe-Donk J, Alshafie GA (2007) Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies. Subcell Biochem 42: 193–212

    PubMed  Google Scholar 

  58. Koehne CH, Dubois RN (2004) COX-2 inhibition and colorectal cancer. Semin Oncol 31 (2 Suppl 7): 12–21

    PubMed  CAS  Google Scholar 

  59. Sporn MB, Dunlop NM, Newton DL, Smith JM (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35(6): 1332–1338

    PubMed  CAS  Google Scholar 

  60. Lotan R (1980) Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 605(1): 33–91

    PubMed  CAS  Google Scholar 

  61. Fields AL, Soprano DR, Soprano KJ (2007) Retinoids in biological control and cancer. J Cell Biochem 102(4): 886–898

    PubMed  CAS  Google Scholar 

  62. Fairfield KM, Hankinson SE, Rosner BA et al. (2001) Risk of ovarian carcinoma and consumption of vitamins A, C, and E and specific carotenoids: a prospective analysis. Cancer 92(9): 2318–2326

    PubMed  CAS  Google Scholar 

  63. De Palo G, Camerini T, Marubini E et al. (1997) Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual. Tumori 83(6): 884–894

    Google Scholar 

  64. De Palo G, Mariani L, Camerini T et al. (2002) Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol 86(1): 24–27

    Google Scholar 

  65. Zhang D, Holmes WF, Wu S et al. (2000) Retinoids and ovarian cancer. J Cell Physiol 185(1): 1–20

    PubMed  CAS  Google Scholar 

  66. Langdon SP, Rabiasz GJ, Ritchie AA et al. (1998) Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo. Cancer Chemother Pharmacol 42(5): 429–432

    PubMed  CAS  Google Scholar 

  67. Gynecologic Oncology Group. Fenretinide followed by surgery compared with surgery alone in preventing ovarian cancer in patients at increased risk. http://clinicaltrials.gov NCT00017134

  68. Harwood CA, Leedham-Green M, Leigh IM, Proby CM (2005) Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. Arch Dermatol 141(4): 456–464

    PubMed  CAS  Google Scholar 

  69. Decensi A, Zanardi S, Argusti A et al. (2007) Fenretinide and risk reduction of second breast cancer. Nat Clin Pract Oncol 4(2): 64–65

    PubMed  Google Scholar 

  70. Bonanni B, Lazzeroni M, Veronesi U (2007) Synthetic retinoid fenretinide in breast cancer chemoprevention. Expert Rev Anticancer Ther 7(4): 423–432

    PubMed  CAS  Google Scholar 

  71. The Women’s Health Initiative Study Group (1998) Design of the Women’s Health Initiative clinical trial and observational study. The Women’s Health Initiative Study Group. Control Clin Trials 19(1): 61–109

    Google Scholar 

  72. Wu W, Celestino J, Milam MR et al. (2008) Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model. Int J Gynecol Cancer 18(2): 329–338

    PubMed  CAS  Google Scholar 

  73. Matsuyama M, Yoshimura R (2008) Peroxisome Proliferator-Activated Receptor-gamma Is a Potent Target for Prevention and Treatment in Human Prostate and Testicular Cancer. PPAR Res 2008 249849

  74. Takahashi H, Yoneda K, Tomimoto A et al. (2007) Life style-related diseases of the digestive system: colorectal cancer as a life style-related disease: from carcinogenesis to medical treatment. J Pharmacol Sci 105(2): 129–132

    PubMed  CAS  Google Scholar 

  75. Sertznig P, Seifert M, Tilgen W, Reichrath J (2007) Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol 212(1): 1–12

    PubMed  CAS  Google Scholar 

  76. Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol 4(10): 578–590

    PubMed  CAS  Google Scholar 

  77. Li YF, Hu W, Fu SQ et al. (2007) Aromatase inhibitors in ovarian cancer: is there a role? Int J Gynecol Cancer

  78. Papadimitriou CA, Markaki S, Siapkaras J et al. (2004) Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 66(2): 112–117

    PubMed  CAS  Google Scholar 

  79. Balbi G, Piano LD, Cardone A, Cirelli G (2004) Second-line therapy of advanced ovarian cancer with GnRH analogs. Int J Gynecol Cancer 14(5): 799–803

    PubMed  CAS  Google Scholar 

  80. Du Bois A, Meier W, Luck HJ et al. (2002) Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer. Ann Oncol 13(2): 251–257

    PubMed  Google Scholar 

  81. Grundker C, Gunthert AR, Millar RP, Emons G (2002) Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation. J Clin Endocrinol Metab 87(3): 1427–1430

    PubMed  CAS  Google Scholar 

  82. Spicer DV, Pike MC (1994) Sex steroids and breast cancer prevention. J Natl Cancer Inst Monogr (16): 139–147

    Google Scholar 

  83. Scheuer L, Kauff N, Robson M et al. (2002) Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20(5): 1260–1268

    PubMed  Google Scholar 

  84. Kauff ND, Satagopan JM, Robson ME et al. (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation 346(21): 1609–1615

  85. Rocca WA, Grossardt BR, de Andrade M et al. (2006) Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 7(10): 821–828

    PubMed  Google Scholar 

  86. Chen KT, Schooley JL, Flam MS (1985) Peritoneal carcinomatosis after prophylactic oophorectomy in familial ovarian cancer syndrome. Obstet Gynecol 66 (3 Suppl): 93S-94S

    PubMed  CAS  Google Scholar 

  87. Weber AM, Hewett WJ, Gajewski WH, Curry SL (1992) Serous carcinoma of the peritoneum after oophorectomy. Obstet Gynecol 80 (3 Pt 2): 558–560

    PubMed  CAS  Google Scholar 

  88. Kjaer SK, Mellemkjaer L, Brinton LA et al. (2004) Tubal sterilization and risk of ovarian, endometrial and cervical cancer. A Danish population-based follow-up study of more than 65.000 sterilized women. Int J Epidemiol 33(3): 596–602

    PubMed  Google Scholar 

  89. Friedman LC, Kramer RM (2005) Reproductive issues for women with BRCA mutations. J Natl Cancer Inst Monogr (34): 83–86

    Google Scholar 

  90. Rebbeck TR, Lynch HT, Neuhausen SL et al. (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 (21): 1616–1622

    PubMed  Google Scholar 

  91. Kauff ND, Domchek SM, Friebel TM et al (2008) Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26 (8): 1331–1337

    PubMed  Google Scholar 

  92. Rocca WA, Grossardt BR, Maraganore DM (2008) The long-term effects of oophorectomy on cognitive and motor aging are age dependent. Neurodegener Dis 5(3–4): 257–260

    Google Scholar 

  93. Somigliana E, Vigano P, Parazzini F et al. (2006) Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol 101(2): 331–341

    PubMed  Google Scholar 

  94. Danforth KN, Tworoger SS, Hecht JL et al. (2007) Breastfeeding and risk of ovarian cancer in two prospective cohorts. Cancer Causes Control 18(5): 517–523

    PubMed  Google Scholar 

  95. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17): 1625–1638

    PubMed  Google Scholar 

  96. Yerushalmi R, Rakowsky E, Sulkes A (2002) Rising CA-125 levels in a patient with ovarian cancer are not always indicative of disease recurrence. Harefuah 141(4): 347–348 410

    PubMed  Google Scholar 

  97. Reeves GK, Pirie K, Beral V et al. (2007) Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 335(7630): 1134

    PubMed  Google Scholar 

  98. Pan SY, Ugnat AM, Mao Y et al. (2004) A case-control study of diet and the risk of ovarian cancer. Cancer Epidemiol Biomarkers Prev 13(9): 1521–1527

    PubMed  Google Scholar 

  99. Stolzenberg-Solomon RZ, Chang SC, Leitzmann MF et al. (2006) Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Am J Clin Nutr 83(4): 895–904

    PubMed  CAS  Google Scholar 

  100. Whittemore AS, Harris R, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Am J Epidemiol 136(10): 1184–1203

    PubMed  CAS  Google Scholar 

  101. Sanner K, Conner P, Bergfeldt K et al. (2008) Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden. Fertil Steril

  102. Rossing MA, Daling JR, Weiss NS et al. (1994) Ovarian tumors in a cohort of infertile women. N Engl J Med 331(12): 771–776

    PubMed  CAS  Google Scholar 

  103. Parazzini F, Negri E, La Vecchia C et al. (1997) Treatment for infertility and risk of invasive epithelial ovarian cancer. Hum Reprod 12(10): 2159–2161

    PubMed  CAS  Google Scholar 

  104. Venn A, Watson L, Bruinsma F et al. (1999) Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 354(9190): 1586–1590

    PubMed  CAS  Google Scholar 

  105. Mills PK, Riordan DG, Cress RD, Goldsmith DF (2005) Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. Cancer Detect Prev 29(2): 124–132

    PubMed  Google Scholar 

  106. Moorman PG, Schildkraut JM, Calingaert B et al. (2005) Menopausal hormones and risk of ovarian cancer. Am J Obstet Gynecol 193(1): 76–82

    PubMed  CAS  Google Scholar 

  107. Moorman PG, Calingaert B, Palmieri RT et al. (2008) Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal women. Am J Epidemiol

  108. Rodriguez C, Patel AV, Calle EE et al. (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285(11): 1460–1465

    PubMed  CAS  Google Scholar 

  109. Zhou B, Sun Q, Cong R et al. (2008) Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol 108(3): 641–651

    PubMed  CAS  Google Scholar 

  110. Kotsopoulos J, Lubinski J, Neuhausen SL et al. (2006) Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 100(1): 83–88

    PubMed  CAS  Google Scholar 

  111. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e.V. (2004) Konsensusempfehlungen zur Hormontherapie (HT) im Klimakterium und in der Postmenopause. Stand September 2006 http://www.dggg.de

  112. Tworoger SS, Lee IM, Buring JE, Hankinson SE (2008) Plasma androgen concentrations and risk of incident ovarian cancer. Am J Epidemiol 167(2): 211–218

    PubMed  Google Scholar 

  113. Li AJ, Elmore RG, Pavelka JC, Karlan BY (2007) Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology. Gynecol Oncol 107(3): 420–423

    PubMed  CAS  Google Scholar 

  114. de Paula FJ, Soares JM jr, Haidar MA et al. (2007) The benefits of androgens combined with hormone replacement therapy regarding to patients with postmenopausal sexual symptoms. Maturitas 56(1): 69–77

    Google Scholar 

  115. Gertig DM, Hunter DJ, Cramer DW et al. (2000) Prospective study of talc use and ovarian cancer. J Natl Cancer Inst 92(3): 249–252

    PubMed  CAS  Google Scholar 

  116. Einhorn N, Sjovall K, Knapp RC et al. (1992) Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol 80(1): 14–18

    PubMed  CAS  Google Scholar 

  117. van Haaften-Day C, Shen Y, Xu F et al. (2001) OVX1, macrophage-colony stimulating factor and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer 92(11): 2837–2844

    Google Scholar 

  118. Bermejo-Perez MJ, Marquez-Calderon S, Llanos-Mendez A (2008) Cancer surveillance based on imaging techniques in carriers of BRCA1/2 gene mutations: a systematic review. Br J Radiol 81(963): 172–179

    PubMed  CAS  Google Scholar 

  119. Michener CM, Ardekani AM, Petricoin EF 3rd et al. (2002) Genomics and proteomics: application of novel technology to early detection and prevention of cancer. Cancer Detect Prev 26(4): 249–255

    PubMed  CAS  Google Scholar 

  120. Rosenthal AN, Menon U, Jacobs IJ (2006) Screening for ovarian cancer. Clin Obstet Gynecol 49(3): 433–447

    PubMed  Google Scholar 

  121. Stevens EV, Liotta LA, Kohn EC (2003) Proteomic analysis for early detection of ovarian cancer: a realistic approach? Int J Gynecol Cancer 13 (Suppl 2): 133–139

    PubMed  Google Scholar 

  122. Conrads TP, Zhou M, Petricoin EF 3rd et al. (2003) Cancer diagnosis using proteomic patterns. Expert Rev Mol Diagn 3(4): 411–420

    PubMed  CAS  Google Scholar 

  123. Khan J (2003) Genomic & proteomic technological advances in cancer research. Pharmacogenomics 4(3): 245–249

    PubMed  Google Scholar 

  124. Ovar A.G.O.e.V.-K (2007) Interdisziplinäre S2k-Leitlinie für die Diagnostik und Therapie maligner Ovarialtumoren. http://www.ago-ovar.de/de/list/4_2_0/leitlinien

  125. AGO-Studiengruppe. http://www.ago-ovar.de/de/subgroup/2_1_0/offene_studien im April 2008

  126. Matei D (2007) Novel agents in ovarian cancer. Expert Opin Investig Drugs 16(8): 1227–1239

    PubMed  CAS  Google Scholar 

  127. Martin L, Schilder R (2007) Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol 25(20): 2894–2901

    PubMed  CAS  Google Scholar 

  128. Ozols RF (2006) Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol 33(2 Suppl 6): 3–11

    Google Scholar 

  129. Coukos G, Conejo-Garcia JR, Roden RB, Wu TC (2005) Immunotherapy for gynaecological malignancies. Expert Opin Biol Ther 5(9): 1193–1210

    PubMed  CAS  Google Scholar 

  130. Du Bois A, Pfisterer J (2005) Future options for first-line therapy of advanced ovarian cancer. Int J Gynecol Cancer 15(Suppl1): 42–50

    Google Scholar 

  131. Pectasides D, Pectasides E (2006) Maintenance or consolidation therapy in advanced ovarian cancer. Oncology 70(5): 315–324

    PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik für Gynäkologie, Gynäkologische Endokrinologie und Onkologie, Universitätsklinikum Gießen und Marburg, Standort Marburg, Baldingerstr., 35043, Marburg, Deutschland

    K.H. Baumann & U. Wagner

Authors
  1. K.H. Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K.H. Baumann.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baumann, K., Wagner, U. Präventionsstrategien beim Ovarialkarzinom. Gynäkologe 41, 513–522 (2008). https://doi.org/10.1007/s00129-008-2143-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00129-008-2143-7

Schlüsselwörter

Keywords

Search

Navigation